Advanced Heart Valve Technology May Allow Patients to Reduce Medication, Complications and Repeat Surgeries

More than 100,000 people need heart valve replacement surgery each year. Thanks to a recent U.S. Food and Drug Administration (FDA) clearance, patients' choices have now expanded to include a replacement valve that requires less blood-thinning medication and can last a patient's lifetime.

65% fewer bleeding events and no increase in stroke risk

Data on On-X's PROACT (Prospective Randomized On-X Anticoagulation Clinical Trial) study affirmed that On-X aortic heart valve patients who reduced their regular blood-thinning medication dosage to maintain an 1.5 to 2.0 INR experienced a 65% overall reduction in bleeding events, with no increase in stroke rate.

Bileaflet prosthetic On-X valve made of pure carbon.

On-X aortic heart valve

Approximately 200,000 patients have received On-X replacement heart valves.

On-X mechanical
Less drugs

Other mechanical
More drugs

Lower blood thinner levels

While clinical guidelines typically recommend mechanical aortic valve patients be managed at an INR level of 2.0 to 3.0, On-X aortic heart valve patients may now be managed 1.5 to 2.0 INR and experience the quality-of-life benefits related to lower doses of blood-thinners.

Additional Operations Increase Costs

While mechanical valves can last a patient's entire lifetime, tissue valves have a more limited lifespan. Tissue valves typically fail or wear out within 10-15 years. This requires tissue valve patients to potentially face the expense, risk and pain of future reoperations for new replacements.

Comparison of mechanical valves

The clinically proven On-X Aortic Heart Valve is made of pure carbon. At a microstructural level, its unique materials and design features give it a more thromboresistant surface than other mechanical valves.

On-X Aortic Heart Valve: smooth carbon with no silicon results in reduced blood damage.



Other mechanical valves: silicon embedded carbon. Rough surface increases chance of platelet sticking, causing blood damage.

Source: On-X Life Technologies, Inc.

Note: INR to be reduced after three months of standard therapy. All patients should consult with their doctor before making any changes to their medications.

*Transcatheter valve-in-valve implant to replace failed tissue valve.